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Snake fang–inspired stamping patch for transdermal 
delivery of liquid formulations
Won-Gyu Bae1*, Hangil Ko2, Jin-Young So1, Hoon Yi2, Chan-Ho Lee1, Dong-Hun Lee3, Yujin Ahn4, 
Sang-Hyeon Lee2, Kyunghun Lee2, Joonha Jun1, Hyoung-Ho Kim5, Noo Li Jeon6, 
Woonggyu Jung4, Chang-Seon Song7, Taesung Kim2, Yeu-Chun Kim8, Hoon Eui Jeong2*
A flexible microneedle patch that can transdermally deliver liquid-phase therapeutics would enable direct use of 
existing, approved drugs and vaccines, which are mostly in liquid form, without the need for additional drug 
solidification, efficacy verification, and subsequent approval. Specialized dissolving or coated microneedle patches 
that deliver reformulated, solidified therapeutics have made considerable advances; however, microneedles that 
can deliver liquid drugs and vaccines still remain elusive because of technical limitations. Here, we present a snake 
fang–inspired microneedle patch that can administer existing liquid formulations to patients in an ultrafast manner 
(<15 s). Rear-fanged snakes have an intriguing molar with a groove on the surface, which enables rapid and efficient 
infusion of venom or saliva into prey. Liquid delivery is based on surface tension and capillary action. The micro-
needle patch uses multiple open groove architectures that emulate the grooved fangs of rear-fanged snakes: Simi-
lar to snake fangs, the microneedles can rapidly and efficiently deliver diverse liquid-phase drugs and vaccines in 
seconds under capillary action with only gentle thumb pressure, without requiring a complex pumping system. 
Hydrodynamic simulations show that the snake fang–inspired open groove architectures enable rapid capillary 
force–driven delivery of liquid formulations with varied surface tensions and viscosities. We demonstrate that 
administration of ovalbumin and influenza virus with the snake fang–inspired microneedle patch induces robust 
antibody production and protective immune response in guinea pigs and mice.
INTRODUCTION
Transdermal drug delivery using microneedle (MN) patches has 
emerged as an attractive alternative to hypodermic injections because 
it enables simple and painless administration of drugs and vaccines 
into a patient’s skin with minimal risk of needle-associated infection 
(1–12). MNs coated with or encapsulating drugs in a thin, flexible 
patch have been extensively studied and have produced consider-
able advances in related fields, demonstrating advantages such as 
controlled drug release, efficacious therapy, ease of use, and low fabri-
cation cost (3, 13–18). In combination with rapidly developing skin- 
attachable flexible electronics techniques, these solid MN patches 
are now incorporating various advanced therapeutic and diagnostic 
functions in flexible patch configurations (13). Despite these advances, 
however, dissolving or coated MNs cannot deliver liquid drug for-
mulations and require additional processing using stabilizers and 
adjuvants to reformulate liquid drugs as solid products, whereas 
most existing formulations of drugs and vaccines are in liquid form 
(1, 3, 4, 19). Solidification of the liquid formulations for the dissolving 
or coated MNs can reduce formulation activity (vaccine activity) (20). 
The viscosity and surface energy of the formulations must also be 
delicately modulated within a narrow range for successful molding 
or coating during the manufacture of the dissolving or coated MNs. 
Furthermore, the reformulation and solidification of liquid formula-
tions require additional efficacy verification and subsequent regula-
tory approval, thereby limiting the widespread use of MN platform 
in the clinical setting.
Hollow MNs have been developed for the delivery of liquid thera-
peutics, but they typically require complex and expensive micro-
electromechanical systems processes for fabrication, and a bulky pump 
is required for drug infusion (8, 21–25). They are therefore difficult to 
prepare in a simple and flexible patch-type configuration, which hind-
ers their clinical use and limits their integration with wearable health 
care devices. Forced drug infusion by an external pump can induce a 
backflow of the injected formulation and can be painful for the patient 
(8, 21–25). A simple and universal patch-type MN platform that can 
directly deliver liquid therapeutics and vaccines represents an unmet 
technical goal. Successful development of such an MN platform opti-
mized for the efficient transdermal delivery of diverse liquid thera-
peutic agents not only would enhance the adoption of MN platform 
in clinical practice but also could provide simple, timely, and safe pre-
ventive measures against highly pathogenic and chronic diseases.
Inspired by the fangs of snakes, here, we report a patch-type MN 
platform that can deliver a variety of existing liquid drugs and vaccines 
into the skin in seconds by simply stamping the MN patch against 
the skin with gentle thumb pressure. This method does not require 
liquid drug reformulation or a complex pumping system. Our MN 
platform contains multiple open grooves on its surface that mimic the 
monogrooved fangs of rear-fanged snakes. Hydrodynamic simulations 
show that the grooves enable rapid capillary force–driven delivery of 
liquid formulations. The fang-inspired MN stamping patch with multi-
ple grooves was used to deliver fluorescein isothiocyanate–conjugated 
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bovine serum albumin (FITC-BSA) and lidocaine into mouse skin 
and to vaccinate guinea pigs and mice with ovalbumin or an inactivated 
pandemic influenza virus, inducing robust antibody production and 
a protective immune response.
RESULTS
Design of the skin-penetrating snake fang–inspired 
stamping patch with multiple grooves
Rear-fanged snakes have a venom delivery system that can quickly 
inject venom or saliva into tissue, although the Duvernoy’s gland in 
these snakes is not able to produce high pressure for delivery (26, 27). 
The structure of the molars in rear-fanged snakes confers their rapid 
injection ability (Fig. 1A). The fangs have an open groove on the 
surface that forms a conduit called a venom tube as the fang penetrates 
the prey animal’s skin. Liquid venom from the Duvernoy’s gland 
runs along the groove and flows into the skin through the venom 
tube to minimize its surface energy (28). As a result, the venom can 
be rapidly and efficiently delivered into the prey’s tissue, without 
the need for a high-pressure system. In contrast, front-fanged snakes 
usually have hollow-tube fangs and exert high pressure from a venom 
gland to inject venom into their prey (29). Traditional hypodermic 
needles and hollow MNs are based on the same delivery mechanism 
as the front-fanged snake. Although this pressure-driven mechanism 
enables quick delivery of liquid formulations, it typically requires a 
strong external driving force for injection (a venom gland, actuator, 
or pump). The narrow tip of the tubular structure can be compressed 
or clogged by the dense dermal or epidermal tissue of the prey’s or 
patient’s skin, necessitating pressure to overcome blockages.
Inspired by the simple and rapid venom delivery mechanism of 
rear-fanged snakes, we devised an MN stamping patch that has open 
grooves on the surface (Fig. 1B). These grooves allow liquid drugs or 
vaccines to be efficiently delivered into the skin without the applica-
tion of high pressure, enabling spontaneous flow driven by surface 
tension and capillary force (28). We designed the MN so that liquid 
formulations can flow down the grooves of the needles and sub-
sequently trickle into the holes formed in the skin. Whereas a snake 
fang has a single groove, we engraved multiple grooves onto the surface 
of each needle to enhance the rate of drug delivery. The multigrooved 
MN (MG-MN) was fabricated by backside exposure lithography using 
poly(ethylene glycol) diacrylate (PEG-DA) (30). PEG-DA was used 
because it is biocompatible and has sufficient mechanical strength for 
skin penetration (31–33). It can also be rapidly cured under ultraviolet 
(UV) light, which enables the low cost and scalable fabrication of the 
MG-MN (32, 34). The resulting MG-MNs are 530 to 635 m in height, 
250 m in base diameter, and 5 m in top radius of curvature.
Figure 1 (C and D) shows the integrated MG-MN stamping patch, 
which comprises two main parts: a polydimethylsiloxane (PDMS) 
chamber and an MN array (see figs. S1 and S2 for details of the fab-
rication process). The PDMS chamber acts as a drug reservoir similar 
to the glands of venomous snakes. The reservoir is designed to contain 
2 l of liquid drug formulation; its capacity can be easily modulated 
by altering the chamber geometry. For example, a reservoir that is 
10 mm (width) by 10 mm (depth) by 1 mm (height) could accom-
modate 100 l of the liquid formulation. Any injectable liquid drug, 
biotherapeutic agent, or vaccine can be loaded into the drug chamber 
through the inlet of the reservoir (Fig. 1D). The MG-MNs were 
formed over a thin PEG-DA film containing microholes (diameter, 
20 m) through which liquid formulations can flow out of the reser-
voir. When the MG-MNs are inserted into the skin with gentle pres-
sure from a thumb, the liquid drugs from the reservoir flow down 
the groove and subsequently run into the skin through capillary 
action. The overall drug delivery mechanism of the MG-MN closely 
resembles the envenomation mechanism of rear-fanged snakes.
To examine the ability of the MG-MN stamping patch to pene-
trate the skin, the needle array was inserted into the dorsal skin of 
mice in vivo under gentle thumb pressure, and the cross-section of 
the skin was examined using optical coherence tomography (OCT) 
and histological sectioning. An OCT image of the skin cross section 
showed that the MG-MNs pierced the stratum corneum (SC) and 
uniformly penetrated the skin (Fig. 1E). The MG-MN could form a 
microscale conduit in the skin for transdermal FITC-BSA delivery 
(Fig. 1F). The MG-MNs were also applied to human and porcine skin, 
which are thicker than murine skin (35). Uniform penetration and 
formation of microscale channels in the skin were observed (fig. S3).
Liquid drug delivery performance of the MG-MNs
The multiple grooves on the surface of the MG-MNs provide multiple 
flow paths to enable rapid, efficient drug delivery. To optimize the 
design of the MG-MNs, we prepared MNs with different numbers 
of grooves: tri-, tetra-, penta-, and hexa-grooved MNs (Fig. 2, A to C, 
fig. S4, and movie S1). All bases of the MG-MNs were designed to 
be inscribed in a circle 250 m in diameter (Fig. 2A); however, the 
MNs differed in height (Fig. 2B). MNs with more grooves were taller 
than those with fewer grooves: 530, 575, 600, and 635 m in height 
for the tri-, tetra-, penta-, and hexa-grooved MNs, respectively. This 
variation was caused by the different slit areas of the photomasks 
used to fabricate the MNs (30). The resulting MNs comprise two 
distinct parts (Fig. 2B): a nongrooved tip that first pierces the skin 
and a grooved wing that forms a conduit with the wall of the incised 
skin (drug channel). To characterize the penetration and cargo 
delivery of the MNs relative to the number of grooves, optical imaging 
of the MG-MNs inserted into the dorsal skin of a mouse to deliver 
FITC-BSA was conducted with a confocal microscope and optical 
coherence microscope (Fig. 2, D to H, and figs. S5 to S7). A three- 
dimensional (3D) reconstruction of the confocal imaging data showed 
that the tip of the MN (red), rather than the entire MN, primarily 
penetrates the skin across the SC (blue) because of deformation of 
the skin (Fig. 2, F to H, and movie S2). FITC-BSA (green) was ob-
served along the drug channel formed by the MG-MNs and the tissue, 
which demonstrates that the transdermal delivery of liquid formula-
tions is possible when using the MG-MNs, as we intended (Fig. 2, E to G).
In contrast to the relationship between the number of grooves 
and height, MNs with more grooves had shorter grooves (Fig. 3A). 
The length of the tip and the length of the groove are important 
factors for obtaining proper skin piercing and drug delivery. Because 
MNs with more grooves have longer tips, piercing of the skin is 
maximized with the hexa-grooved MN (360 m), and it is minimized 
with the tri-grooved MN (179 m) (Figs. 2H and 3B). Top views of 
the confocal microscopy and optical coherence microscopy (OCM) 
images also showed that different hole formations were created in 
the skin depending on the type of MN inserted. MNs with more 
grooves created larger holes in the skin because of the deeper pene-
tration (Figs. 2, D and E, and 3C). Different drug channels were ob-
served for different MG-MNs. For example, the tri-grooved MN could 
only create a small gap in the skin, and FITC-BSA was observed only 
within a very narrow region around the MN. By contrast, FITC-BSA was 
observed in a broader vicinity surrounding the penta- and hexa-grooved 
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Fig. 1. Design of the snake fang–inspired stamping patch. (A) Illustrations of the venom delivery system of the rear-fanged snake. Venom from the Duvernoy’s gland 
runs along the grooved fang and rapidly flows, under capillary action, into the tissue of the prey. (B) Photograph of the snake fang–inspired MN array. The inset shows a 
scanning electron microscopy image of the MG-MN, which has two distinct parts: a nongrooved tip and a grooved wing. After the nongrooved tip pierces the skin, the 
grooved wing forms a conduit with the wall of the incised skin. (C) Photograph of the integrated MN patch held on a human fingertip. The patch consists of an MN array 
and a PDMS chamber. The inset shows an MN formed over a thin PEG-DA film that has microholes (diameter, 20 m) through which liquid formulations can trickle out of 
the chamber (drug outlet). (D) Conceptual diagrams of the patch. Liquid drugs are loaded into the chamber through the inlet of the reservoir before use. When the patch 
is applied over the skin with gentle pressure from a thumb, liquid drugs loaded in the reservoir roll down the grooves (yellow arrows) and enter the skin by capillary action. 
(E) OCT image of a cross section of the dorsal skin from a mouse that was injected with the MN array. The image indicates uniform penetration of the array into the skin 
through the SC. (F) Bright-field, fluorescence and merged micrographs (from left) of a histological section of mouse skin after insertion and removal of an MN patch loaded 
with FITC-BSA. Scale bars, 300 m (B); 100 m (B, inset); 5 mm (C); 100 m (C, inset); 300 m (E); and 300 m (F).
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MNs, showing that the penta- and hexa-grooved MNs can generate 
multiple channels with large effective radii in the skin (Fig. 2E). Different 
MG-MNs also exhibited different mechanical strengths. The fracture 
force was greater for the MNs with more grooves: 0.9 and 2.1 N per 
needle for the tri- and hexa-grooved MNs, respectively (Fig. 3D). This 
indicates that the MG-MNs are robust enough to penetrate the skin 
without structural fracture regardless of the number of grooves (fig. S8). 
Consequently, the hexa-grooved MN has the greatest piercing depth, 
drug channel diameter, and fracture strength. However, it has the 
shortest groove; the groove length plays an important role in guiding 
liquid into the skin. The deeper penetration depth of the hexa- grooved 
MN could also result in pain (36). To avoid this, we used the penta- 
grooved MN for the in vivo tests performed in this study. The penta- 
grooved MN has a proper penetration depth for painless insertion 
and a sufficient channel size and groove length for efficient drug 
delivery. It also has high mechanical strength.
Hydrodynamic simulation of liquid drug delivery  
in the MG-MNs
To understand the hydrodynamic behavior of liquid-phase drugs in 
the MG-MN, we performed computational fluid dynamics simula-
tion using COMSOL Multiphysics with the two-phase flow module in 
which the Navier-Stokes equation and a level set method are coupled. 
Our hydrodynamic simulation results showed that transdermal 
delivery occurred in an ultrafast manner with the aid of a capillary 
force caused by the groove structure of the MG-MN. Figure 4 (A and B) 
shows the schematics of a single groove of the MG-MN inserted into 
the skin. Once the MG-MN pierces the skin and penetrates the tissue, 
the groove of the MN and the cut and exposed side of the tissue form 
an upper wide and lower narrow channel through which a drug 
droplet can be delivered (Fig. 4, A and B). Figure 4 (C and D) shows 
the time-lapse drug delivery process and velocities of a liquid droplet 
in the groove, respectively (movie S3). Initially, under gentle thumb 
pressure, the droplet moves slowly along the open groove toward 
the entrance of the closed channel. However, as soon as the droplet 
reaches the entrance of the closed channel, the velocity sharply in-
creases up to 0.46 m s−1. This increase occurs because the leading 
(lower) edge of the tube produces a much stronger capillary force 
than the following (upper) edge that remains outside the tube (37, 38). 
In addition, when the MN partially penetrates the skin, a closed 
channel is formed by the MN groove and the tissue, while an open 
channel is also formed by the upper part of the groove and the air. 
This contributes to the low-pressure drug delivery that is achieved 
by our MG-MN stamping patch: The MN has an extensive surface 
A
B
C
D
E
F
G
H
Tri-grooved MN Quad-grooved MN Penta-grooved MN Hexa-grooved MN
SC
(i) (ii) (iii) (iv)
(i) (ii) (iii) (iv)
Fig. 2. Rational design of MG-MNs for the transdermal delivery of liquid drugs. (A and B) Scanning electron microscopy images of the top (A) and side (B) views of 
(i) tri-grooved, (ii) tetra-grooved, (iii) penta-grooved, and (iv) hexa-grooved MNs. (C) 3D reconstruction images of confocal micrographs of MG-MNs. Top row shows top 
view; bottom row shows side view. (D) Top views of OCM micrographs showing the different types of holes created in mouse skin by MNs with different numbers of grooves. 
(E to H) Top views (E), side views (F and G), and cross-sectional views (H) of confocal micrographs showing the penetration of MNs (red) with different numbers of grooves loaded 
with FITC-BSA (green) into the dorsal skin of mice across the SC (blue). The SC is removed in (G) to better visualize the delivery of FITC-BSA into the skin. Scale bars, 100 m (A to H).
 at ULSAN NATIO
NAL INSTITUTE O
F SCIENCE AND TECHNO
LO
G
Y on August 22, 2019
http://stm
.sciencem
ag.org/
D
ow
nloaded from
 
Bae et al., Sci. Transl. Med. 11, eaaw3329 (2019)     31 July 2019
S C I E N C E  T R A N S L A T I O N A L  M E D I C I N E  |  R E S E A R C H  A R T I C L E
5 of 11
area that is exposed to the tissue and the air. Only the tip of conven-
tional hollow MNs and hypodermic needles is exposed to the tissue, 
requiring a strong external force for injection.
We also investigated the effects of surface tension and viscosity 
of the liquid droplet on the drug delivery process. Figure 4D shows 
the calculated velocities of droplets with 0.5× and 0.25× smaller sur-
face tension values compared to that of water. As shown, before the 
droplet approaches the entrance of the closed channel, the droplet 
velocities are similar to each other regardless of the surface tension 
values. When the droplets with smaller surface tension contact to the 
entrance of the closed channel, their velocities rapidly increase (as 
with the case of the water droplet). However, the peak velocities of 
the droplets are relatively smaller (0.3 and 0.15 m s−1 for drops with 
0.5× and 0.25× surface tension, respectively) compared to that of the 
standard water drop (0.46 m s−1), which can be easily understood by 
considering the fact that surface tension is the most important factor for 
the capillary motion of liquid droplet in microscale channels. None-
theless, the enhanced velocities of the liquid droplets in the closed 
channel are ~2 orders higher than velocities in the open channel. 
In addition to the surface tension, we also investigated the effects of 
drop viscosity on the drug delivery process in the MG-MN. As shown 
in Fig. 4D, when the viscosity of the droplet is two or five times higher 
than that of a water droplet but other properties remain constant, the 
droplet takes a longer time to reach the entrance of the closed channel. 
Viscous shear stresses on the droplet induced by the wall are pro-
portional to the viscosity of the droplet; however, once the droplet 
reaches the closed channel, the droplet velocity sharply increases for 
droplets with two and five times viscosi-
ties. These results indicate that our MG-
MN stamping patch can deliver diverse 
liquid-phase therapeutic agents with 
varied surface tensions and viscosities, 
using surface tension and capillary ac-
tion without necessitating a complex 
pumping system.
In vivo transdermal delivery 
of liquid formulations 
with the snake fang–inspired 
stamping patch
Transdermal liquid drug delivery using 
the MG-MN stamping patch was tested 
in vivo in mice using FITC-BSA–loaded 
patches (Fig. 5, A and B). Fluorescence 
images taken after applying the stamping 
patch for different lengths of time showed 
that FITC-BSA was delivered into the 
skin of mice within seconds of insertion 
(<15 s; Fig. 5, A and B). Direct comparison 
of the relative fluorescence intensities 
indicated that prolonged MN insertion 
was beneficial: More liquid was delivered 
into the skin with extended contact. A 
sevenfold increase in photons was de-
tected after 15 s of insertion compared 
to 5 s of insertion (Fig. 5C). Although 
the liquid drug delivery from the MN 
reservoir occurs rapidly, drug absorption 
into the tissue takes time. Quantitative 
fluorescence image analysis of histological sections of the penetration 
sites further confirmed that longer insertion times allowed more 
FITC-BSA to diffuse into the skin (Fig. 5, B and D). Nonetheless, 
FITC-BSA could be delivered into the skin within 15 s using the 
MG-MN patch.
We also examined the diffusion of drug into the skin. Figure 5 
(E and F) shows fluorescence images taken before and after a 15-s 
injection of the FITC-BSA–loaded MN stamping patch. The fluo-
rescence intensity of FITC-BSA immediately after MN removal was 
similar to the intensity before removal. The intensity decreased over 
the course of 15 min after the removal of the patch, which indicates 
that the delivered FITC-BSA gradually diffused into the skin of the 
mice (Fig. 5, F and G). To further demonstrate the efficacious delivery 
of clinically relevant liquid formulations, we administered lidocaine, 
a widely used local anesthetic, to mice using the stamping patch. A 
2-l dose of 4% lidocaine was administered to mice using different 
insertion durations, and the amount of drug delivered for each dura-
tion was quantified using high-performance liquid chromatography 
(HPLC). As shown in Fig. 5H, 13.35, 33.94, and 141.01 g cm−2 of 
lidocaine were detected in the skin corresponding to insertion times of 
5, 10, and 15 s, respectively, which demonstrates that an anesthetic agent 
can be rapidly deployed to the skin using an MG-MN stamping patch.
Vaccination with the snake fang–inspired stamping patch
To assess the effectiveness of vaccinations using the MG-MN 
stamping patch, we investigated humoral immune responses after 
MN vaccination. MG-MN patches loaded with 2 l of ovalbumin 
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Fig. 3. Skin-penetration performance of MG-MNs. (A) Total height and groove height of various MG-MNs. (B and 
C) Pierced depth (B) and hole diameter (C) in mouse skin for different types of MG-MNs. (D) Fracture forces of MNs 
with different numbers of grooves. Data represent means ± SD (n = 5).
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antigen (OVA) without adjuvants were applied to the dorsal skin of 
guinea pigs (n = 10) for two different insertion times, 5 and 15 s 
(Fig. 6A). The same dose of OVA was administered to guinea pigs 
via intramuscular injection for comparison, and a 2-l aliquot of 
phosphate-buffered saline (PBS) was injected using MNs as a control. 
Analysis of anti–OVA-specific immunoglobulin G (IgG) 14 and 
28 days after immunization using enzyme-linked immunosorbent 
assay (ELISA) showed enhanced OVA-specific IgG titers in all groups 
except the control (Fig. 6A). In particular, guinea pigs immunized 
with the MG-MNs (15 s of insertion) showed enhanced OVA-specific 
IgG titers compared to intramuscularly immunized guinea pigs. We 
hypothesize that this is because a large number of immunologically 
active cells and antigen-presenting cells (APCs) exist in the epidermis 
or upper layers of the dermis (39–41). Therefore, MN-based skin 
vaccination can potentially result in stronger immune responses with 
lower antigen concentrations (so-called dose-sparing effect) com-
pared to the traditional intramuscular vaccination (42–45). Such dose- 
sparing can compensate for the limited injection volume capacity of 
the MN platform compared to that of the conventional hypodermic 
needle injection. The MG-MN injections administered for 15 s also 
induced higher IgG titers than the injection case for 5 s, which is 
consistent with the results shown in Fig. 5. OVA-specific IgG titers 
were reduced for all groups on day 28, although the MN-immunized 
groups still showed higher IgG titers compared to other groups.
To further explore the potential of the MG-MN stamping patch 
as a tool for vaccination, we administered inactivated pandemic/2009 
H1N1 influenza virus (pH1N1) to mice (n = 10) via MG-MN or intra-
muscular injections, and we analyzed the hemagglutination (HA) 
inhibition (HI) titers in the mice. Compared to the control group, 
all immunized groups showed enhanced HI titers 14 and 28 days 
after immunization (Fig. 6B). MN immunization with 5 s of inser-
tion resulted in much lower HI titers than intramuscular injection. 
In contrast, immunization with MNs for a longer insertion time (15 s) 
induced higher HI titers than those induced by intramuscular vac-
cination. This result agreed with those of prior studies reporting 
enhanced immune responses of MN influenza vaccination compared 
to the intramuscular vaccination because of the dose-sparing effect 
caused by the higher number of APCs in the skin (43–45). The dif-
ference in the immune responses between the 5-s OVA-treated group 
(Fig. 6A) and the 5-s pH1N1-treated group (Fig. 6B) could have 
originated from the different immunogenicity degrees of the vaccines 
(46, 47). To validate the immunogenicity and protective efficacy of 
the influenza immunization, we challenged the immunized groups 
with lethal influenza virus 4 weeks after the vaccination. The control 
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(unimmunized) group exhibited a sharp decrease in body weight 
after exposure to the pH1N1 and did not survive more than 8 days 
after exposure (Fig. 6, C and D). In contrast, a single administration 
of the vaccine with an MN patch with an insertion time of 15 s pro-
tected all of the mice against the lethal exposure to the virus, and the 
mice recovered their normal body weight after an initial reduction. 
This shows that our MG-MNs not only enable simple and fast vac-
cination but also induce robust protective immune responses with a 
single administration.
DISCUSSION
Over the past few decades, MN technology has rapidly evolved, and 
translation of the MN technology into the clinical setting is now 
of immense interest in this field (42, 48). To translate the MNs, a 
number of issues must be considered, including the scalable aseptic 
manufacturing of MNs, adopting a patient-friendly and error-free 
MN insertion method, consequences of deposition of MN residues 
in the skin, and the storage stability of MNs (42). Regarding the 
scalable and aseptic production issue, compared to silicon MNs that 
require multiple fabrication steps and clean room facilities or dis-
solving MNs that require relatively long solidification times, our 
MG-MN has advantages in that the MN array can be fabricated 
within a few tens of seconds using UV-curable and biocompatible 
PEG-based polymer. However, our MN requires an additional drug 
chamber, whereas dissolving MNs load drugs or vaccines in the MN 
body itself without the need for the chamber, which would poten-
tially increase the fabrication cost. For patient safety, sterilization of 
the MNs is essential during manufacturing. According to a previous 
study, sterilization of MNs by -irradiation, steam autoclave, or micro-
wave heating could damage the cargos loaded within them (49). 
Therefore, for our MG-MNs, the drugs or vaccines must be loaded 
in the chamber after sterilization of the MN device.
Consistent skin insertion with intuitive patient-friendly feedback 
also requires consideration. Although diverse applicators have been 
devised to enhance the consistency in the MN skin insertion with 
feedback functions, their use is less patient friendly and would in-
crease the product cost. In contrast, although manual insertion is 
simple, it would increase the interindividual variability in skin inser-
tion. It can also be difficult for patients to ensure that they properly 
apply MNs to the skin (50). For our MNs, patients could perceive 
the proper delivery of the drugs or vaccines by observing the eleva-
tion of the residual liquid formulations in the chamber. However, 
incorporating a more intuitive feedback mechanism into the device 
would enhance patient compliance. To this end, a low-cost pressure- 
indicating sensor film (PISF) can be assembled over the chamber of 
the MG-MN because of its simple and flexible thin film architecture 
(50). The PISF exhibits colorations in response to external pressure 
application. Vicente-Pérez et al. (50) successfully demonstrated that 
the simple incorporation of the PISF into their hydrogel-forming 
MN could provide appropriate feedback to patients to guarantee 
proper insertion with minimal cost. The deposition of MN residues 
into the skin could lead to adverse effects in the patient skin, a consid-
eration for dissolving MNs. Unlike the dissolving MNs, our MG-MN 
did not appear to leave any MN residue in the skin upon its removal 
after a few or a few tens of seconds of skin insertion. However, this 
also indicates that the MG-MN may not be appropriate for a pro-
longed long-term cargo delivery. For controlled long-term cargo 
delivery using our MNs, microfluidic components such as valves 
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fluorescence intensity of FITC-BSA in the in vivo test (F). (H) The amounts of lidocaine 
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would be required to be incorporated into the device. Because our 
MN devices contain liquid formulations in the chamber, they require 
cold chain for storage stability as with the storage of conventional 
liquid formulations, which would potentially limit the use of the MN 
in developing countries. Additional factors should be carefully con-
sidered to improve the MG-MN design toward its translation into 
clinical practice (42).
Hypodermic needle injection for liquid drug or vaccine delivery 
works well. However, a set of prior studies demonstrated distinct 
advantages of MN-based delivery over conventional needle injection, 
including improved patient compliance, acceptability, immuno-
genicity, and safety (1, 42). Enhanced patient compliance is among 
the most important aspects of the MN technique because MNs 
painlessly pierce the epidermis without stimulating dermal nerves in 
a minimally invasive manner. Because of the enhanced compliance, 
patients and health care professionals showed positive attitudes 
about the use of MNs over conventional intramuscular injection in 
several prior studies (42). For example, according to a prior study 
by Norman et al. (51), influenza vaccination by MNs instead of hypo-
dermic injection resulted in an increased vaccination intent from 44 
to 65%. MN technology is especially useful for patients who require 
regular repeated drug injection or blood sampling. Norman et al. (52) 
reported that the use of hollow MNs for insulin delivery in children 
and adolescents with type 1 diabetes 
noticeably reduced injection pain com-
pared to injection by a subcutaneous 
catheter. Mooney et al. (53) reported that 
child participants showed strong support 
and enhanced acceptability of MN-based 
blood sampling compared to sampling 
using traditional hypodermic needles. 
Furthermore, a study of MN acceptability 
by Birchall et al. (54) reported that public 
(100%) and health care professional 
(75%) participants were overall positive 
in the use of MNs because of the benefits 
of the MN technology (reduced pain, 
tissue damage, and risk of infection trans-
mission) compared to conventional 
needle injections, as well as the potential 
for self-administration. The positive per-
ception and high acceptability of the 
MN vaccination from general public and 
health care professionals were also re-
ported in a study by Arnou et al. (55). 
In addition to enhanced patient com-
pliance, MN vaccination leads to a 
stronger immune response with a lower 
dose of vaccine compared with the con-
ventional intramuscular injection as 
described above without the potential 
dangers of hypodermic needles (3). By 
considering the limited manufacturing 
and supply capacity of influenza vaccines 
in the event of a pandemic, the develop-
ment of an MN-based influenza vaccina-
tion is highly desirable as a dose-sparing 
vaccination strategy (56). Such a dose- 
sparing effect was verified in this study 
with the MG-MN as in prior reports (42–45).
In the present study, a limited number of liquid formulations 
(FITC-BSA, lidocaine, OVA, and influenza vaccine) were tested to 
investigate transdermal liquid drug delivery of the MG-MNs in mice 
and guinea pigs. Additional studies accessing the efficacy and safety 
of the MG-MN patch using a wider variety of liquid drugs and vac-
cines in larger animal models and human participants are required 
to translate the MG-MN technique to clinical trials. Nonetheless, 
with its simple fabrication process and rapid liquid drug delivery 
capability, we expect that this MG-MN technique can provide a 
valuable platform for the simple, fast, and smart administration of 
diverse liquid drugs, biotherapeutic agents, and vaccines against 
diverse pathogenic and chronic diseases.
MATERIALS AND METHODS
Study design
The objective of this study was to investigate the feasibility and efficacy 
of transdermal delivery of liquid-phase therapeutics and vaccines 
using MG-MN patches. First, the MG-MNs with four different de-
signs of open grooves (tri-, tetra-, penta-, and hexa-grooved MNs) 
were prepared, and their skin penetration performances were eval-
uated using mouse, pig, and human skin and confocal microscopy, 
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OCM, and OCT analyses. Then, transdermal liquid drug delivery 
using the MG-MNs was evaluated by the injection of FITC-BSA 
and lidocaine into live mice. Last, the immune responses of guinea 
pigs were investigated by the application of OVA-loaded MG-MN 
to the dorsal skin of guinea pigs for two different insertion times 
(5 and 15 s). The same dose of OVA was administrated to guinea 
pigs via intramuscular injection for comparison. The immune re-
sponses of mice were also studied by the administration of inactivated 
pH1N1 to mice via MG-MN or intramuscular injections. A 2-l 
aliquot of PBS was injected using MNs as controls. In vivo studies 
involving OVA vaccination were performed in guinea pigs randomly 
housed in four groups of 10 guinea pigs each. In vivo studies involv-
ing pH1N1 vaccination were performed in BALB/c mice randomly 
housed in four groups of 10 mice each. The investigators were blinded 
to group allocation during experiments and data assessment. All 
animal procedures performed in this study were reviewed, approved, 
and supervised by the Institutional Animal Care and Use Committee 
of Konkuk University (permit number KU14123). All experiments 
on the human participant were approved by the Institutional Review 
Board (IRB) of the Ulsan National Institute of Science and Technology 
(IRB number UNISTIRB-18-63-A).
Fabrication of a snake fang–inspired stamping patch
The MG-MN patch comprises two main parts: a PDMS chamber 
and an MN array.
Preparation of PDMS chamber
The PDMS chamber, which serves as a drug reservoir, was fabricated 
by replica molding of a patterned silicon master with a PDMS pre-
polymer (Sylgard 184, Dow Corning). The patterned silicon master 
was prepared by forming positive microstructures on a silicon sub-
strate with a photolithographic process using SU-8 100 (MicroChem) 
as a photoresist. Then, PDMS base mixed with a curing agent in a 
10:1 weight ratio was poured onto the silicon master. After degassing 
and thermal curing at 65°C for 2 hours, the cured PDMS was peeled 
off from the master, resulting in a PDMS drug chamber. A circular 
hole, which serves as an inlet for loading drugs into the chamber, was 
formed on the back side of the chamber using a disposable biopsy 
punch (diameter, 1 mm; Integra Miltex).
Preparation of MN array
The MN array was formed over a thin PEG-DA film containing micro-
holes. The PEG-DA film with microholes was prepared by applying 
a MIMIC (micromolding in capillaries) technique. A PDMS pillar 
array (pillar diameter, 20 m; height, 100 m) was first prepared 
using a replica molding process. Then, the PDMS pillar array 
was placed on a flat PDMS slab. Subsequently, precured PEG-DA 
(Mn = 250; Sigma-Aldrich) mixed with 0.5 weight % 2-hydroxy-2- 
methylpropiophenone (Sigma-Aldrich), a water-soluble photoinitiator, 
was introduced into the gap between the PDMS slab and the pillar 
array by capillary action. The PEG-DA mixture was cured under 
UV light (intensity, 20 mJ s−1; exposure time, 30 s). The solidified 
PEG-DA membrane was peeled off of the PDMS pillar array, resulting 
in a PEG-DA membrane with holes. MN arrays were fabricated 
over the PEG-DA membrane by backside exposure lithography. 
First, the prefabricated PEG-DA membrane was placed and aligned 
on a photomask with transparent multiple blade patterns (fig. S1, A 
and B). Then, a coverslip was placed on the PEG-DA membrane at 
a distance using spacers (thickness, 1 mm) to form a space with uni-
form thickness in which precured PEG-DA enters through capillary 
action (fig. S1C). Subsequent UV exposure through the photomask 
generated MN arrays on the PEG-DA membrane with microholes 
(fig. S1, D to F). The cured MN array was rinsed with ethanol and 
deionized water several times and was then dried with a nitrogen gun 
to remove uncured residual PEG-DA.
Integration of PDMS chamber and MN array
To assemble the PDMS chamber and the MN array, the backside of 
the PEG-DA membrane was treated with oxygen plasma for 60 s 
(60 W, PDC-32G, Harrick Scientific) after dehydration at 60°C for 
1 hour. A droplet of (3-aminopropyl)triethoxysilane (APTES) 
(Sigma-Aldrich) was uniformly applied to the backside of the PEG-DA 
membrane. The surface of the PDMS chamber was also treated with 
oxygen plasma and then brought in contact with the APTES-treated 
PEG-DA membrane for irreversible bonding of these two parts, re-
sulting in an integrated MG-MN patch (fig. S1, G to I).
Manual skin penetration tests
The MG-MNs were inserted into the skin of a human volunteer 
(male, 27 years old), pigs, and mice under gentle thumb pressure, 
and the cross sections were examined using OCT, OCM, and histo-
logical sectioning.
In vivo experiment
Preparation of antigen in mice
pH1N1, A/Korea/01/2009 (H1N1), was propagated in the allantoic 
cavities of 9- to 11-day-old specific pathogen–free embryonated 
chicken eggs. Seventy-two hours after inoculation, allantoic fluid con-
taining pH1N1 was harvested and purified by low-speed centrifuga-
tion (2000g, 30 min, 4°C), and the pH1N1 from the supernatants was 
pelleted using ultracentrifugation (30,000g, 1.5 hours, 4°C). The 
pelleted virus was resuspended in PBS solution (pH 7.4; Thermo 
Fisher Scientific) and purified using 20 to 50% (w/v) discontinuous 
sucrose density gradient purification (150,000g, 2.5 hours, 4°C). The 
pH1N1 was inactivated by binary ethylenimine. Then, the amount 
of proteins was measured using a QuantiPro bicinchoninic acid 
assay kit (Sigma-Aldrich) according to the manufacturer’s instruc-
tions. Antigens were diluted to solutions of 0.5 g l−1 for the MN 
immunization and 0.1 g l−1 for the intramuscular injection.
Immunogenicity and protective efficacy in mice
Six-week-old female BALB/c mice (Orient Bio) were housed in four 
groups of 10 mice each: mice that were immunized by MN for 5 s 
(MN 5 s group), mice that were immunized by MN for 15 s (MN 15 s 
group), mice that were immunized via an intramuscular route (intra-
muscular group), and mice that were immunized with PBS (PBS 
control group). Each mouse in the immunization groups received 1 g 
of antigen. Mice were intraperitoneally anesthetized with Avertin 
(375 mg kg−1). During anesthesia, the hair on the back was removed 
with a depilatory cream (Veet, Reckitt Benckiser); the back was 
washed with warm water and 70% ethanol (Sigma-Aldrich) for 5 min 
after application of the removal cream. Then, the mice in the MN 5 
and 15 s groups were immunized with 2 l of pH1N1 antigen solution 
by an MN patch for 5 or 15 s, respectively. The mice in the intra-
muscular group were injected via an intramuscular route with 10 l 
of pH1N1 antigen solution. After 4 weeks of immunization, the 
mice were anesthetized by an intraperitoneal injection of Avertin 
(375 mg kg−1) and challenged intranasally with 90 l of 106 median 
embryo infectious dose of pH1N1 for the challenge experiment. The 
weight and survival rate were monitored for 14 days after the chal-
lenge. A body weight loss of more than 25% as compared to the body 
weight on the day before the challenge was considered to have reached 
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a humane end point; these mice were euthanized. HI antibody re-
sponses in mouse sera collected at 2 and 4 weeks after immunization 
were measured using an HI test. For the HI assay, serum samples 
were first treated with a receptor-destroying enzyme (Denka Seiken) 
by overnight incubation at 37°C and then for 30 m at 56°C. Sera 
were serially diluted, mixed with 4 HA units of pH1N1, and incu-
bated for 30 m at room temperature before adding 0.5% chicken red 
blood cells. The reciprocal of the highest serum dilution preventing 
HA was scored as the HI titer.
Preparation of antigen in guinea pig
Ovalbumin (Sigma-Aldrich) was used as the antigen. Ovalbumin 
was diluted to solutions of 15 g l−1 for the MN immunization and 
3 g l−1 for the injection via the intramuscular route using PBS 
solution.
Immunogenicity and protective efficacy in guinea pig
Five-week-old male guinea pigs weighing 200 to 250 g (Orient Bio) 
were housed in four groups of 10 guinea pigs each: guinea pigs that 
were immunized by MN for 5 s (MN 5 s group), guinea pigs that were 
immunized by MN for 15 s (MN 15 s group), guinea pigs that were 
immunized via the intramuscular route (intramuscular group), and 
guinea pigs that were immunized with PBS (PBS control group). Each 
guinea pig in the immunization groups received 30 g of OVA. 
During anesthesia, the hair on the back was removed with a depilatory 
cream; the back was washed with warm water and 70% ethanol for 
5 min after application of the removal cream. Then, the guinea pigs 
in the MN 5 and 15 s groups were immunized with 2 l of ovalbumin 
solution by an MN patch for 5 or 15 s, respectively. The mice in the 
intramuscular group were injected via an intramuscular route with 
10 l of ovalbumin solution. Serum was prepared, and OVA-specific 
IgG was measured by ELISA according to the manufacturer’s recom-
mendations (catalog number MBS727414, MyBioSource). Samples 
were analyzed in duplicate, and absorbance was read at 405 nm.
Statistical analysis
Datasets were analyzed using Welch’s analysis of variance (ANOVA) 
test. In all cases, P values of <0.05 were considered statistically sig-
nificant. Calculations were performed using SPSS version 10.1. 
Primary data are reported in data file S1.
SUPPLEMENTARY MATERIALS
stm.sciencemag.org/cgi/content/full/11/503/eaaw3329/DC1
Materials and Methods
Fig. S1. Fabrication of the snake fang–inspired MN patch.
Fig. S2. Optimization of UV exposure conditions for the fabrication of MNs with robust 
structures and sharp tips.
Fig. S3. Penetration of MG-MNs into the human and porcine skin.
Fig. S4. Fabrication of MG-MNs.
Fig. S5. Automated skin penetration test.
Fig. S6. Schematic of the spectral domain OCT system.
Fig. S7. Schematic of the OCM system.
Fig. S8. Mechanical property test of MN arrays.
Data file S1. Primary data.
Movie S1. 3D confocal reconstruction of the hexa-grooved MN.
Movie S2. 3D reconstruction showing the penetration of the hexa-grooved MN (red) loaded 
with FITC-BSA (green) into the dorsal skin of mice across the SC (blue).
Movie S3. Simulation of liquid drug delivery in a single groove of MG-MN.
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immunized by microneedle patch or intramuscular injection. This flexible patch platform offers a versatile method
anesthetic, and a vaccine to guinea pigs and mice. Mice showed similar protection against influenza when 
microneedles with open grooves that transdermally delivered dye-labeled proteinaceous solutions, liquid
rapidly deliver liquid formulations through the skin. Inspired by rear-fanged snakes, the authors fabricated 
. developed flexible patches using microneedles toet alpain associated with hypodermic needle injections. Bae 
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